Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 ...

A new review by Dr. Ruyuan Wang and an international team of researchers explores the complex interactions between the innate and adaptive immune ...

Initially mistaken for neutrophils, a population of atypical macrophages appears in the lungs after severe viral infection, ...

In this randomized controlled trial, axatilimab effectively managed symptoms in patients with recurrent or refractory graft ...

T cell therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors. A study demonstrates that a different immunotherapy approach ...

A bioinformatics pipeline describes 390 putative, novel inhibitory receptors, to facilitate targeted therapeutic strategies for diverse immune cell types in cancer therapy.

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) is set to present significant advancements in cancer treatment at ...

In the fight against cancer, chimeric antigen receptor T cell (CAR-T) therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors.

When there are too many macrophages in a tissue, and they all secrete MCP-1, this can cause inflammation and damage to the tissue. Our findings suggest that blocking the sodium channel or the MCP-1 ...

Despite being a remarkable medical advancement, organ transplants still face the critical issue of rejection by the immune ...

The company plans to use the Series B investment to advance the development of its macrophage therapies in inflammatory and ...